【摘要】 目的 观察香菇多糖联合信迪利单抗治疗胰腺癌的抗肿瘤效果及对患者免疫应答的影响。方法 选取95例胰腺癌患者，按照随机数字表法分为常规组和联合组。常规组47例采用信迪利单抗治疗，联合组48例采用香菇多糖结合信迪利单抗治疗。均随访1年，比较两组的肿瘤标志物、免疫功能、近期疗效，及短期生存情况。结果 治疗后，联合组的CEA、CA199、CA242、T细胞表面抗原CD3~+、CD4~+均高于常规组，CD8~+低于常规组，差异均有统计学意义(P<0.05); INF-γ、IL-2、IL-4、客观缓解率(ORR)、疾病控制率(DCR)均高于常规组(P<0.05);随访期间，联合组1年内的中位无进展生存期(PFS)、中位总生存期(OS)均高于常规组(P<0.05)。结论 香菇多糖联合信迪利单抗治疗胰腺癌，能通过增强患者免疫应答而产生更加理想的抗肿瘤效果，对改善患者近期疗效及短期预后均有积极意义。更多还原

【Abstract】 Objective To observate the anti-tumor effect of Lentinan combined with Sintilimab in pancreatic cancer and its effect on patient immune response. Methods 95 patients with pancreatic cancer were randomly divided into two groups. 47 cases in the conventional group were treated with Sintilimab. The combined group of 48 cases were treated with Lentinan combined with Sintilimab. Both groups were followed up for 1 year to compare their tumor markers, immune function, recent efficacy, and short-term survival. Results The levels of CEA, CA199, CA242, T cell surface antigen CD3~+, CD4~+ in the combined group were higher than those in the conventional group, while CD8~+ was lower than that in the conventional group. The differences were statistically significant(P<0.05). The levels of INF-γ, IL-2 and IL-4, objective response rate(ORR) and disease control rate(DCR) were all higher than those in the conventional group. The differences were statistically significant(P<0.05). During the follow-up period, the median progression free survival(PFS) and median overall survival(OS) within one year in the combined group were higher than those in the conventional group, and the differences were statistically significant(P<0.05). Conclusion Lentinan combined with Sintilimab in the treatment of pancreatic cancer produces more ideal anti-tumor effect by enhancing the immune response of patients, which has positive significance in improving the short-term efficacy and short-term prognosis of patients.更多还原